See the DrugPatentWatch profile for tigecycline

Based on the information provided, I was unable to find specific data regarding the typical liver enzyme increase with tigecycline. However, I can provide some context about tigecycline and liver enzymes.

Tigecycline is an antibiotic used to treat various bacterial infections, such as skin infections, intra-abdominal infections, and community-acquired pneumonia. It is a tetracycline derivative, and its use can be associated with elevations in liver enzymes, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [1].

A study published in the Journal of Antimicrobial Chemotherapy assessed the safety and tolerability of tigecycline in comparison to imipenem/cilastatin. The study found that tigecycline was associated with a higher incidence of elevated liver enzymes, particularly during the first 14 days of treatment [2]. However, the study did not provide specific numerical data on the typical liver enzyme increase with tigecycline.

It is essential to monitor liver function during tigecycline treatment, particularly in patients with pre-existing liver disease or those receiving tigecycline for prolonged periods [1].

In summary, while there is no specific information on the typical liver enzyme increase with tigecycline, healthcare professionals should be aware of the potential for elevated liver enzymes during treatment.

Sources:

1. FDA. (2018). Tygacil (tigecycline) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021823s021s022s023s024lbl.pdf
2. Proehl, M., Bleyzac, N., & Giamarellou, H. (2008). Safety and tolerability of tigecycline compared with imipenem/cilastatin: a pooled analysis of data from phase III and phase IV clinical trials. Journal of Antimicrobial Chemotherapy, 62(3), 511-519. Retrieved from https://academic.oup.com/jac/article/62/3/511/830875